Ftse Mib
34.242,49
0,75%
DAX
18.430,05
1,42%
S&P 500
5.187,70
0,13%
NASDAQ
16.332,56
-0,10%
Bitcoin
62.778,01
0,71%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Mirati Therapeutics Inc (MRTX) Mirati Therapeutics Inc (MRTX) Notizie

Mirati Therapeutics Inc

MRTX
58,70
0,00 (0,00%)
07 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/2/202420:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:13EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/2/202422:05EDGAR2Form 15-12G - Securities registration termination [Section..
25/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
24/1/202402:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202415:31EDGAR2Form S-8 POS - Securities to be offered to employees in..
23/1/202415:30EDGAR2Form POSASR - Post-effective Amendment to an automatic shelf..
23/1/202415:28EDGAR2Form POS AM - Post-Effective amendments for registration..
23/1/202415:27EDGAR2Form POS AM - Post-Effective amendments for registration..
23/1/202414:48EDGAR2Form 8-K - Current report
18/1/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202414:00PRNUSEuropean Commission Approves KRAZATI (adagrasib) as a..
09/1/202423:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202322:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19/12/202322:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202313:30EDGAR2Form 8-K - Current report
14/12/202323:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:30EDGAR2Form 8-K - Current report
06/12/202314:29EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
01/12/202322:43EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24/11/202322:45EDGAR2Form 8-K - Current report
15/11/202314:49EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/11/202313:30PRNUSMirati Therapeutics Receives Positive Opinion from CHMP for..
06/11/202314:05EDGAR2Form 8-K - Current report
06/11/202314:00PRNUSMirati Therapeutics Reports Third Quarter 2023 Financial..
06/11/202313:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202322:19PRNUSMirati Therapeutics Receives Approval from the MHRA for..
02/11/202312:30EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
02/11/202312:30GLOBEKura Oncology and Mirati Therapeutics Enter into Clinical..
23/10/202323:31EDGAR2Form PREM14A - Preliminary proxy statements relating to..
17/10/202322:00PRNUSMirati Presents Late-Breaking Results Evaluating the..
11/10/202313:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/10/202313:35EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/10/202313:33EDGAR2Form 8-K - Current report
10/10/202313:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
Apertura: Min: Max:
Chiusura: 58,70

La tua Cronologia

NASDAQ
MRTX
Mirati Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network